In the last trading session, 1.1 million shares of the Sagimet Biosciences Inc (NASDAQ:SGMT) were traded, and its beta was 2.55. Most recently the company’s share price was $4.13, and it changed around -$0.26 or -5.92% from the last close, which brings the market valuation of the company to $126.68M. SGMT currently trades at a discount to its 52-week high of $20.71, offering almost -401.45% off that amount. The share price’s 52-week low was $2.39, which indicates that the current value has risen by an impressive 42.13% since then. We note from Sagimet Biosciences Inc’s average daily trading volume that its 10-day average is 2.03 million shares, with the 3-month average coming to 905.60K.
Sagimet Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended SGMT as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Sagimet Biosciences Inc is expected to report earnings per share of -0.63 for the current quarter.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Instantly SGMT has showed a red trend with a performance of -5.92% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.61 on recent trading dayincreased the stock’s daily price by 10.41%. The company’s shares are currently down -8.22% year-to-date, but still down -9.73% over the last five days. On the other hand, Sagimet Biosciences Inc (NASDAQ:SGMT) is -30.47% down in the 30-day period. We can see from the shorts that 4.17 million shares have been sold at a short interest cover period of 1.37 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 31.17% from its current value. Analyst projections state that SGMT is forecast to be at a low of $6 and a high of $6.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Sagimet Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 33.66 percent over the past six months and at a 39.47% annual growth rate that is well above the industry average of 16.50%. The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -16.23%.
SGMT Dividends
Sagimet Biosciences Inc’s next quarterly earnings report is expected to be released in February.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 14.11% of Sagimet Biosciences Inc shares, and 66.94% of them are in the hands of institutional investors. The stock currently has a share float of 77.94%.
Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust were the top two Mutual Funds as of Sep 30, 2024 . The former held 763.99 shares worth $3.16 million, making up 2.49% of all outstanding shares. On the other hand, BlackRock Health Sciences Term Trust held roughly 408.12 shares worth around $1.69 million, which represents about 1.33% of the total shares outstanding.
